Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care
Main finding · eGFRResult — go to the resultDifference 1.2 ml/min per 1.73 m²Authors' conclusion
In individuals with type 2 diabetes, treatment with SGLT2i was associated with better preservation of renal function compared with GLP-1RA, as evidenced by slower decline in eGFR. These findings reinforce SGLT2i as preferred agents for renal protection in this patient population.
Study context
- Population
- New users of diabetes medications with T2D; predominantly male, aged 61 years, 10 year diabetes duration, baseline HbA1c 64 mmol/mol (8.0%), BMI 33 kg/m², chronic kidney disease (CKD) in 23%matched cohort
- Participants
- 5,701 vs 5,701
- Exposure
- SGLT2i vs GLP-1 RA
- SGLT2in = 5,701
- GLP-1RAn = 5,701reference
- Outcome
- Change in eGFR (mixed-effects models)
- Follow-up
- Median 2.1 years
Methodological detailsmulticentre, observational, new users, propensity score matched
- Multicentre
- Observational
- New users
- Propensity score matched
Main finding
eGFR
Difference
1.2 ml/min per 1.73 m²
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
Albuminuria change
- No differences detected in albuminuria change
Worsening CKD class, BP and HbA1c
- SGLT2i had lower rates of worsening CKD class and favourable BP changes vs GLP-1RA, despite lesser HbA1c decline
eGFR decline, participants without baseline CKD
- SGLT2i reduced eGFR decline better than GLP-1RA
Original publication
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care. Diabetologia. Published 23 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →